Poels, R.; Drent, E.; Lameris, R.; Katsarou, A.; Themeli, M.; van der Vliet, H.J.; de Gruijl, T.D.; van de Donk, N.W.C.J.; Mutis, T.
Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma. Int. J. Mol. Sci. 2021, 22, 1096.
https://doi.org/10.3390/ijms22031096
AMA Style
Poels R, Drent E, Lameris R, Katsarou A, Themeli M, van der Vliet HJ, de Gruijl TD, van de Donk NWCJ, Mutis T.
Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma. International Journal of Molecular Sciences. 2021; 22(3):1096.
https://doi.org/10.3390/ijms22031096
Chicago/Turabian Style
Poels, Renée, Esther Drent, Roeland Lameris, Afroditi Katsarou, Maria Themeli, Hans J. van der Vliet, Tanja D. de Gruijl, Niels W. C. J. van de Donk, and Tuna Mutis.
2021. "Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma" International Journal of Molecular Sciences 22, no. 3: 1096.
https://doi.org/10.3390/ijms22031096
APA Style
Poels, R., Drent, E., Lameris, R., Katsarou, A., Themeli, M., van der Vliet, H. J., de Gruijl, T. D., van de Donk, N. W. C. J., & Mutis, T.
(2021). Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma. International Journal of Molecular Sciences, 22(3), 1096.
https://doi.org/10.3390/ijms22031096